Pharmaceutical Investing Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial
Pharmaceutical Investing Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin) in combination with KEYTRUDA (pembrolizumab) for Triple Negative Breast Cancer
